{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complicated+Urinary+Tract+Infection",
    "query": {
      "condition": "Complicated Urinary Tract Infection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complicated+Urinary+Tract+Infection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:45:40.058Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01345929",
      "title": "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection",
        "Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "CXA-201",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 558,
      "start_date": "2011-06-20",
      "completion_date": "2013-09-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345929"
    },
    {
      "nct_id": "NCT01110408",
      "title": "A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infections or Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Doripenem placebo",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Cefepime placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/clavulanate potassium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 41,
      "start_date": "2010-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Orange, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110408"
    },
    {
      "nct_id": "NCT01595438",
      "title": "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftazidime - Avibactam ( CAZ-AVI)",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)",
          "type": "DRUG"
        },
        {
          "name": "or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 598,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 3,
      "location_summary": "Sylmar, California • Royal Oak, Michigan • Lima, Ohio",
      "locations": [
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Lima",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01595438"
    },
    {
      "nct_id": "NCT02420366",
      "title": "Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Tract Infection, Complicated",
        "Acute Pyelonephritis",
        "Hospital Acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 257,
      "start_date": "2014-05",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 12,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Somers Point",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420366"
    },
    {
      "nct_id": "NCT05204368",
      "title": "Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Combination of Imipenem/Cilastatin and XNW4107",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evopoint Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 780,
      "start_date": "2023-03-30",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204368"
    },
    {
      "nct_id": "NCT02168946",
      "title": "Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection Complicated",
        "Acute Pyelonephritis",
        "Hospital Acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Abdominal Infection"
      ],
      "interventions": [
        {
          "name": "Vabomere",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2014-07",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 20,
      "location_summary": "Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168946"
    },
    {
      "nct_id": "NCT02714595",
      "title": "Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthcare-associated Pneumonia (HCAP)",
        "Bloodstream Infections (BSI)",
        "Hospital Acquired Pneumonia (HAP)",
        "Complicated Urinary Tract Infection (cUTI)",
        "Sepsis",
        "Ventilator Associated Pneumonia (VAP)"
      ],
      "interventions": [
        {
          "name": "Cefiderocol",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2016-09-07",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 6,
      "location_summary": "Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02714595"
    },
    {
      "nct_id": "NCT00690378",
      "title": "Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection"
      ],
      "interventions": [
        {
          "name": "NXL104/ceftazidime",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 137,
      "start_date": "2008-11",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690378"
    },
    {
      "nct_id": "NCT03357614",
      "title": "Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Sulopenem",
          "type": "DRUG"
        },
        {
          "name": "Sulopenem-Etzadroxil/Probenecid",
          "type": "DRUG"
        },
        {
          "name": "Ertapenem",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iterum Therapeutics, International Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1395,
      "start_date": "2018-09-18",
      "completion_date": "2019-12-14",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 15,
      "location_summary": "Bellflower, California • Chula Vista, California • La Mesa, California + 11 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03357614"
    },
    {
      "nct_id": "NCT01644643",
      "title": "Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection",
        "Complicated Intra-abdominal Infection"
      ],
      "interventions": [
        {
          "name": "Ceftazidime - Avibactam ( CAZ-AVI)",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 345,
      "start_date": "2013-01",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-05-22T09:45:40.058Z",
      "location_count": 2,
      "location_summary": "Shreveport, Louisiana • Lima, Ohio",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Lima",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644643"
    }
  ]
}